IN8bio Inc (INAB)
0.99
0.00 (0.00%)
USD |
NASDAQ |
May 01, 10:40
IN8bio Cash from Financing (TTM): 27.04M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 27.04M |
September 30, 2023 | 13.44M |
June 30, 2023 | 21.20M |
March 31, 2023 | 9.637M |
December 31, 2022 | 8.988M |
September 30, 2022 | 8.029M |
June 30, 2022 | 33.81M |
Date | Value |
---|---|
March 31, 2022 | 33.29M |
December 31, 2021 | 32.96M |
September 30, 2021 | 33.22M |
June 30, 2021 | 17.64M |
March 31, 2021 | 18.40M |
December 31, 2020 | 24.52M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
8.029M
Minimum
Sep 2022
33.81M
Maximum
Jun 2022
21.70M
Average
21.20M
Median
Jun 2023
Cash from Financing (TTM) Benchmarks
Jaguar Health Inc | 34.23M |
Aptevo Therapeutics Inc | 5.998M |
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |
iBio Inc | 10.68M |